---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046845"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T02:17:18.333310+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program

## Summary
- New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.
- Prior ATM with H.C. Wainwright for up to $40M terminated; ~$18.6M had been sold under that program.
- No costs or payments associated with termination of prior ATM.
- Sales will be made as at-the-market offerings on Nasdaq subject to customary conditions.
- Proceeds from any sales will be used for general corporate purposes as described in the prospectus supplement.

## SEC filing metadata
- accession: 0001104659-25-046845
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925046845/0001104659-25-046845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925046845/tm2514418d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046845
- JSON: https://secwatch.observer/filing/0001104659-25-046845.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.